Jeff Bland
Jeff Bland is a functional medicine practitioner. His work focuses on the relationship between dietary interventions, immune function regulation, cellular aging, and chronic disease prevention.
36 claims checked on air: 3 context 8 contradicted 4 overstated 15 supported 6 unverified
What they said on air - supported
Immune cell rate of aging can be reduced by 47% in 90 days.
"In 90 days, you would reverse your immune health by 47%. GUEST1: Reduce the rate of aging of the immune cells by 47%." (said at 0:00:00)
The claim refers to a 90-day pilot clinical trial evaluating a Tartary buckwheat-derived polyphenol supplement in 50 healthy participants, which assessed epigenetic clocks and cellular markers of immune aging. While the pilot study documented significant changes in epigenetic age clocks and immune markers over the 90-day intervention, the evidence is very low certainty given the preliminary nature of the pilot study, small sample size, and lack of extensive replication in large randomized controlled trials.
There are approximately 80 distinct medical diagnoses classified as autoimmune diseases.
"There are 80-some-odd different diagnoses of autoimmune diseases that have different names, different reimbursement codes like MS or lupus or Hashimoto's" (said at 0:04:06)
Standard biomedical literature and health authorities (such as the National Institutes of Health and the Autoimmune Association) recognize more than 80 distinct autoimmune conditions—commonly cited as '80+' or between 80 and 100 distinct disorders—including systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, and type 1 diabetes mellitus.
Macrophage immune cells penetrate the vascular endothelial layer into the intimal layer of blood vessel walls, where they engulf oxidized low-density lipoprotein (LDL) and subparticles through the release of oxidants.
"So it goes through the first layer, which is at the endothelial level, and it gets into the intimal level, and then eventually it sees if there's something funny going on in there. And if it sees something funny going on, it does what it's supposed to do: get rid of funny business and attack it as a foreigner. So it does a macrophage engulfment, and it goes through its process, which is killing by chemical warfare through the release of oxidants. So what could be inside that vessel wall that would precipitate that? It could be many different things, one of which could be oxidized LDL." (said at 0:09:06)
The speaker's statement accurately summarizes the foundational mechanism of atherogenesis. Endothelial activation/injury permits the infiltration and retention of lipoproteins into the subendothelial intima, where they undergo oxidative modification. Circulating monocytes/macrophages transmigrate across the endothelium into the intima, recognize and engulf oxidized LDL, and transform into lipid-laden foam cells amidst ongoing inflammatory and oxidative processes.
Microplastics have been detected inside human arterial walls.
"And so now it's microplastics, which are now found in artery walls." (said at 0:10:07)
A prospective multicenter study published in 2024 examined excised carotid artery plaque specimens from 257 patients undergoing carotid endarterectomy. Using pyrolysis-gas chromatography-mass spectrometry, stable isotope analysis, and electron microscopy, researchers detected polyethylene in carotid artery plaques from 58.4% of patients and polyvinyl chloride in 12.1%, confirming the presence of micro- and nanoplastics within human arterial atheromas.
A Stanford Medical School study co-authored by David Furman demonstrated that the majority of human immune system function is non-heritable and shaped by environmental influences.
"A seminal paper was published out of Stanford Medical School a number of years ago. One of the authors was a former podcast guest that you'd had, David Furman, asking the question, is our immune system genetically controlled or is it non-genetically controlled?... And the answer is that a very small amount of our immune system function is hardwired into our genes. The majority of our immune system function is not heritable." (said at 0:13:42)
A 2015 twin study from Stanford University School of Medicine (Brodin et al., co-authored by David Furman and Mark M. Davis, published in Cell) evaluated 210 healthy monozygotic and dizygotic twins across 204 immune parameters, including cell population frequencies, cytokine responses, and serum proteins. The study found that 77% of the measured parameters were dominated (>50% of variance) and 58% almost completely determined (>80% of variance) by non-heritable influences, with cumulative environmental exposures and infections (such as cytomegalovirus) shaping the majority of immune variation over time.
A study conducted by Oura and Stanford showed that biometric data from the Oura Ring could detect infection onset days before clinical symptoms appeared.
"And then I found out that the company Oura was rapidly involved with studying with Stanford the relationship between the biometrics that come off the Oura Ring with that of immune system function. And they published a paper showing that you could detect some days before you got an infection, based on your Oura Ring data, whether you were going to have an immune problem." (said at 0:17:36)
The claim is supported by published literature on consumer wearable devices during the COVID-19 pandemic. Studies evaluating biometric data from wearable devices—including the large-scale TemPredict study utilizing the Oura Ring (which tracks continuous dermal temperature, heart rate, and heart rate variability) as well as wearable studies from Stanford University—demonstrated that aberrant physiological metrics could detect infection onset approximately 2.5 to 3 days before symptom onset or diagnostic testing.
Some individuals with a BMI over 40 have normal insulin, blood sugar, lipids, low hs-CRP, and no apparent chronic disease.
"One type I call friendly fat. This is like Santa Claus. That person doesn't have altered metabolic function. Their insulin's fine. Their blood sugar is fine. Their lipids are fine. Their hs-CRP is low. They have no apparent chronic disease. Yet, their BMIs are over 40." (said at 0:18:15)
Observational cohort studies confirm that a subset of individuals with class III obesity (BMI ≥ 40 kg/m²) exhibit a "metabolically healthy obesity" (MHO) phenotype. These individuals display normal fasting glucose, normal insulin sensitivity, normal lipid profiles, lower systemic inflammatory markers (such as hs-CRP), and an absence of overt cardiometabolic disease, though longitudinal studies note that this metabolic profile can transition to an unhealthy state over time.
C-reactive protein (CRP) is synthesized by hepatocytes in the liver.
"C-reactive protein is a is a molecule made by your body's immune system, or actually by the hepatocytes, that then is related to inflammatory burden." (said at 0:27:02)
C-reactive protein (CRP) is a well-established acute-phase reactant synthesized predominantly by hepatocytes in the liver in response to pro-inflammatory cytokine signaling (such as interleukin-6 and interleukin-1β) during systemic inflammation and infection.
A high-sensitivity C-reactive protein (hs-CRP) level above 1 to 2 mg/L indicates a chronic inflammatory condition.
"And this high-sensitivity variant gives you a much more sensitive determination of your immune cell inflammatory potential, and anything above, say, 1 to 2 on that test is indicative that there's some kind of a chronic inflammatory condition that may be present." (said at 0:27:15)
Standard clinical guidelines established by the American Heart Association and the Centers for Disease Control and Prevention categorize high-sensitivity C-reactive protein (hs-CRP) levels into risk tiers based on low-grade systemic inflammation: <1.0 mg/L indicates low risk, 1.0 to 3.0 mg/L indicates moderate risk (reflecting mild chronic inflammation), and >3.0 mg/L indicates high risk. An hs-CRP level above 1 to 2 mg/L thus reflects the presence of low-grade chronic systemic inflammation.
- supports: Clinical usefulness of very high and very low levels of C-reactive protein across the full… (Circulation 2004) · cited 514x in the literature
"High-sensitivity C-reactive protein (hsCRP) is a strong independent risk factor for cardiovascular events, and levels of hsCRP of <1, 1 to <3, and > or =3 mg/L have been suggested to define low-, moderate-, and high-risk groups." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) i… (The American heart hospital journal 2004) · cited 40x in the literature
"Levels of hsCRP <1, 1-3, and >3 mg/L correspond to lower, moderate, and higher risk of cardiovascular events at all levels of the Framingham Risk Score and at all levels of metabolic syndrome." (abstract, passage verified)
pubmed - supports: High sensitivity C-reactive protein in clinical practice. (The American heart hospital journal 2003) · cited 29x in the literature
"Among apparently healthy men and women, levels of high sensitivity C-reactive protein of <1, 1-3, and >3 mg/L distinguish between those at low, moderate, and high risk for future cardiovascular disease, respectively." (abstract, passage verified)
pubmedfull study (doi)
Shinya Yamanaka won the Nobel Prize for the discovery of Yamanaka factors.
"So Yamanaka factors won a Nobel Prize for their discovery. Uh Professor Yamanaka—are these genes that are associated with longevity." (said at 0:29:40)
Shinya Yamanaka was awarded the 2012 Nobel Prize in Physiology or Medicine (shared jointly with Sir John B. Gurdon) for discovering that mature cells can be reprogrammed to become pluripotent stem cells (iPSCs) using a specific set of transcription factors (Oct3/4, Sox2, Klf4, and c-Myc, commonly referred to as the Yamanaka factors).
A goat produces almost a gram of vitamin C per day endogenously in its liver.
"In fact, the goat makes over um almost a gram a day of vitamin C in its own liver." (said at 0:44:55)
Comparative biochemical research shows that mammals—with specific exceptions such as humans, other primates, fruit bats, and guinea pigs—possess the enzyme L-gulonolactone oxidase and synthesize ascorbic acid (vitamin C) endogenously in the liver. In adult mammals such as goats and other ruminants, baseline hepatic synthesis produces substantial amounts of vitamin C daily (often estimated at tens of milligrams per kilogram of body weight, amounting to several grams per day in an adult animal).
The flavoring agents of dill and spearmint are enantiomers of the same molecule, carvone, differing only in optical rotation (R-carvone and S-carvone).
"So what is the molecule that produces the flavoring of dill and the flavoring of spearmint? It's the same molecule. It just tastes different. It's called carvone. Now now here is the point of the of my story. It turns out the only difference between the carvone that's in dill and the carvone that's in spearmint is the way that it rotates plane-polarized light. One rotates plane-polarized light to the right; the other rotates plane-polarized light to the left." (said at 0:46:35)
The flavoring components of spearmint and dill/caraway are indeed enantiomers (mirror-image stereoisomers) of carvone. (R)-(-)-carvone provides the characteristic spearmint odor/flavor (levorotatory, rotating plane-polarized light to the left), whereas (S)-(+)-carvone is the primary constituent of caraway and dill seed oil (dextrorotatory, rotating plane-polarized light to the right).
A 90-day human trial of 50 subjects taking 1,200 mg/day of Himalayan Tartary buckwheat polyphenols showed up to a 20-fold alteration in immune cell epigenetic patterns regulating the ceramide kinase and COP9 pathways.
"That the signal was so strong on our immune system uh of these um 50 subjects that we had in the trial that some of the epigenetic patterns in their um immune uh genes were amplified or altered by 20-fold... they were regulating two interesting pathways or networks. One is called the ceramide kinase network, and the other is called COP9." (said at 0:55:07)
A 2024 pilot clinical trial evaluated the epigenetic effects of a standardized Tartary buckwheat (Fagopyrum tataricum) polyphenol concentrate in 50 healthy human subjects over 90 days. The study examined peripheral immune cells using DNA methylation profiling (epigenetic age clocks and gene ontology pathway analyses) and reported significant intervention-related modifications in immune cell epigenetic patterns and pathways related to immunity and longevity. However, the evidence certainty is low because it is a single open-label pilot study (NCT05234203) with limited sample size and preliminary surrogate biomarker endpoints.
A pilot trial analyzing immune cell aging clocks found that Himalayan tartary buckwheat reduced the rate of immune cell aging by 47% over three months.
"And so what this then translated to when we did the algorithms of uh aging clock analysis of the immune cells is that we reduced the rate of aging of those immune cells by 47% over the course of three months." (said at 1:00:16)
A 2024 pilot clinical trial (PMID: 39628466) evaluated the effects of 90 days (approximately three months) of daily supplementation with a standardized Himalayan Tartary buckwheat (Fagopyrum tataricum) polyphenol concentrate in 50 healthy adults aged 18–85 years. Using epigenetic clock algorithms (such as DunedinPACE and other DNA methylation metrics) and deconvolution methods on peripheral blood immune cells, the study reported significant intervention-related reductions in biological and immune aging clocks. Because the findings come from a single small, preliminary pilot trial, certainty is low.
The study showing a 47% reduction in immune cell aging was an unblinded, non-placebo-controlled pilot trial with a small number of subjects.
"This was a pilot trial, was a small number of subjects, uh wasn't blinded, wasn't placebo-controlled." (said at 1:00:40)
The speaker accurately describes the study design of the trial evaluating a Himalayan Tartary buckwheat polyphenol supplement on epigenetic markers of immune aging (PMID 39628466). It was an open-label, single-arm pilot study conducted in 50 healthy participants without blinding or a placebo control group.
Fact-checked episodes
Publications
No PubMed publication profile has been built for this speaker yet.